查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015246

苯酮尿症治療市場：依治療方法、給藥途徑及分銷管道分類－2026-2032年全球市場預測

Phenylketonuria Treatment Market by Treatment Type, Route of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年苯酮尿症治療市值為 9.6608 億美元，預計到 2026 年將成長至 10.0915 億美元，複合年成長率為 5.84%，到 2032 年將達到 14.3778 億美元。

主要市場統計數據
基準年 2025 9.6608億美元
預計年份：2026年 1,009,150,000 美元
預測年份 2032 1,437,780,000 美元
複合年成長率 (%) 5.84%

一個重點突出、權威的框架，用於確定苯酮尿症治療的優先順序，在背景下提出臨床要求、相關人員的期望和策略決策流程。

苯酮尿症 (PKU) 是一個獨特的領域，它融合了罕見疾病的生物學、終身臨床管理和不斷湧現的治療創新。本文概述了目前的研究現狀：遺傳學知識日趨成熟，新生兒篩檢在許多醫療系統中已成為常規，患者支持活動在臨床和商業層面都蓬勃發展。本文首先說明了核心臨床挑戰，例如如何持續降低苯丙胺酸水平、如何終生維持神經認知功能，以及影響長期生活品質的治療依從性的實際挑戰。

清楚概述了分子層面的創新、不斷發展的護理模式以及支付方的價值框架如何重塑苯酮尿症治療的未來。

苯酮尿症的治療格局正在經歷一場變革，這主要得益於分子醫學的突破、醫療服務模式的轉變以及支付方期望的改變。基因療法和先進的酵素替代療法不再僅僅停留在理論階段，而是正在推進臨床試驗，其療效持久性、載體安全性以及長期監測等方面也日益受到關注。同時，藥物治療領域的創新旨在降低日常管理的複雜性，透過靶向代謝途徑的藥物來降低苯丙胺酸水平，從而改善認知功能預後。

對 2025 年美國關稅改革將如何影響苯酮尿症治療的供應鏈策略、製造商決策和支付方合約趨勢進行嚴格分析。

貿易和關稅體系的政策變化會對特藥治療、生產決策和供應鏈韌性產生深遠影響。美國2025年實施的關稅調整促使整個苯酮尿症（PKU）價值鏈上的相關人員重新評估籌資策略、定價模式和庫存計畫。為此，製造商正在探索供應商多元化，以降低成本風險，同時保持對生物製藥和複雜小分子化合物的嚴格品管和監管合規性。

一項全面的、以細分為主導的綜合分析，將治療方法、給藥途徑、患者年齡層和配銷通路與策略發展和准入考慮因素聯繫起來。

精細的市場細分方法揭示了臨床需求、給藥途徑和分銷管道趨勢之間的交集，展現了它們對治療路徑和商業性機會的影響。根據治療類型，該領域包括基因療法和酵素替代療法、營養補充劑和藥物治療，其中藥物治療類別又細分為培伐酶和鹽酸沙丙蝶呤。每種療法都有其獨特的臨床特徵、給藥要求和用藥依從性考量。這些治療差異決定了臨床醫生在頻譜嚴重程度的疾病中選擇哪些干預措施，以及製造商如何突出起效時間、監測要求和長期安全性數據等差異化優勢。

一項策略性區域評估揭示了世界各地醫療保健系統、篩檢計劃和生產能力的差異如何影響苯酮尿症治療的可近性。

區域趨勢對於理解臨床實踐、監管流程和報銷系統如何影響苯酮尿症（PKU）治療方法的可及性和分配至關重要。在美洲，完善的新生兒篩檢計畫和集中式專科醫療中心為早期診斷和長期照護提供了支持，但對於居住在都會區以外的患者以及需要特殊管理和監測的治療方法而言，獲取治療仍然面臨挑戰。該地區的政策對話日益強調基於價值的合約和擴大高影響力治療方法的保險覆蓋範圍，敦促製藥公司製定能夠引起臨床相關人員和保險公司共鳴的循證方案。

經營團隊深入了解臨床數據的深度、生產策略以及綜合患者支援服務的提供，這些因素決定了苯酮尿症治療開發公司的競爭優勢。

苯酮尿症治療領域的競爭格局由產品差異化、臨床證據深度和生態系參與策略共同塑造。領先的研發公司正投資於長期臨床試驗和真實世界數據（REW），以證明其能夠持續控制生化指標並取得良好的功能性療效，同時也在不斷改進生產流程，以最佳化擴充性和成本效益。與專科診所、患者權益組織和診斷實驗室建立策略合作夥伴關係，有助於加強患者識別、登記註冊和用藥依從性支持項目，從而提升治療效果。

一系列可操作的建議，旨在協調臨床試驗設計、患者支援服務、供應彈性和支付方合作，以加速部署和普及。

行業領導者必須將科學目標與切實可行的商業和市場准入策略相結合，以確保治療進展能夠轉化為可衡量的患者獲益。首先，研發公司應優先考慮包含有意義的功能性終點、患者報告結局和按年齡分層分析的試驗設計，以滿足臨床和支付方的決策標準。其次，整合用藥依從性支援服務（數位監測、營養諮詢和遠端醫療追蹤）可以顯著改善真實世界療效，並加強與支付方的協商。第三，應透過供應商多元化、區域製造夥伴關係以及針對溫度敏感治療方法和腸外療法的緊急時應對計畫來增強供應鏈的韌性。

認知到資料的局限性，採用透明、多方面的研究途徑，結合專家訪談、監管審查和文獻整合，可以產生可靠且可操作的見解。

本研究整合了多種證據來源，以得出平衡且可重複的結論。主要研究包括對臨床專業人員、專科藥劑師和患者權益倡導組織負責人進行結構化訪談，以了解他們在診斷、治療啟動和長期管理方面的實踐經驗。次要研究涵蓋了同行評審文獻、監管指導文件、臨床試驗註冊數據和衛生政策分析，以全面檢驗臨床療效、安全性以及不斷變化的監管預期。透過交叉檢驗資料資訊來源，提高了資料的完整性；並透過記錄訪談方案、參與者選擇標準和分析框架，確保了調查方法的透明度。

簡明扼要地闡述了臨床創新、營運韌性和相關人員合作之間的相互作用，以此作為苯酮尿症治療中實現患者持續獲益的途徑。

總之，苯酮尿症的治療模式正處於十字路口，科學進步與可及性和永續性的實際需求交匯融合。基因療法、酵素替代療法和藥物療法的進步正在拓展治療選擇，但要最大限度地發揮其潛力，需要製定綜合策略，解決用藥依從性、監測以及支付方的證據要求等問題。供應鏈和政策的變化，包括關稅相關的調整和區域製造舉措，凸顯了營運韌性與臨床創新同等重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按治療方法分類的苯酮尿症治療市場

  • 基因療法和酵素替代療法
  • 營養補充品
  • 藥物治療
    • 佩格巴里茲
    • 鹽酸沙丙蝶呤

第9章 苯酮尿症治療市場：依給藥途徑分類

  • 口服
  • 腸外

第10章 苯酮尿症治療市場：依分銷管道分類

  • 離線
  • 線上

第11章 苯酮尿症治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 苯酮尿症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 苯酮尿症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國苯乙酮尿症治療市場

第15章：中國苯酮尿症治療市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • American Gene Technologies
  • APR Applied Pharma Research sa
  • BioMarin Pharmaceuticals Inc
  • Codexis, Inc.
  • Daiichi Sankyo Co. Ltd.
  • Galen Limited
  • Homology Medicines, Inc.
  • Nestle SA
  • PIAM Farmaceutici SPA
  • Pluvia AS
  • PTC Therapeutics, Inc.
  • Relief Therapeutics Holding SA
  • Sanofi group
  • Synlogic
  • Travere Therapeutics, Inc.
  • Ultragenyx Pharmaceutical Inc.
Product Code: MRR-030EE485160A

The Phenylketonuria Treatment Market was valued at USD 966.08 million in 2025 and is projected to grow to USD 1,009.15 million in 2026, with a CAGR of 5.84%, reaching USD 1,437.78 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 966.08 million
Estimated Year [2026] USD 1,009.15 million
Forecast Year [2032] USD 1,437.78 million
CAGR (%) 5.84%

A focused and authoritative framing of phenylketonuria treatment priorities that contextualizes clinical imperatives, stakeholder expectations, and strategic decision pathways

Phenylketonuria (PKU) represents a unique intersection of rare disease biology, lifelong clinical management, and advancing therapeutic innovation. This introduction situates readers within the contemporary landscape where genetic understanding has matured, newborn screening is routine in many health systems, and patient advocacy has catalyzed both clinical and commercial momentum. The narrative opens by clarifying core clinical challenges: durable reduction of phenylalanine levels, preservation of neurocognitive outcomes across the lifespan, and the practicalities of treatment adherence that influence long-term quality of life.

From a stakeholder perspective, clinicians, payers, and patient groups align around the need for therapies that meaningfully reduce treatment burden while delivering consistent biochemical control. At the same time, innovators and manufacturers are navigating complex regulatory pathways, differentiated trial designs, and emergent real-world evidence demands. This introduction outlines how these stakeholder priorities converge into strategic imperatives for product development, health system integration, and equitable access. By framing the discussion in clinical, commercial, and policy contexts, it prepares decision-makers to evaluate subsequent sections on shifting paradigms, tariff impacts, segmentation insights, geographic dynamics, and actionable recommendations.

An incisive overview of how molecular innovations, care model evolution, and payer value frameworks are reshaping the future of phenylketonuria treatment

The therapeutic landscape for phenylketonuria is undergoing transformative shifts driven by breakthroughs in molecular medicine, changing care delivery models, and evolving payer expectations. Gene therapy and advanced enzyme substitution approaches are no longer purely theoretical; they are progressing through clinical stages with growing attention on durability, vector safety, and long-term monitoring. Concurrently, innovations in pharmacological approaches aim to reduce daily management complexity, with agents targeting metabolic pathways to lower phenylalanine and improve cognitive outcomes.

These therapeutic advances intersect with operational shifts. Personalized nutrition management is increasingly supported by digital monitoring and telehealth-enabled dietetics, improving adherence and longitudinal data capture. Payers and health technology assessment bodies are adapting value frameworks to rare disease contexts, placing higher emphasis on patient-reported outcomes and functional endpoints alongside biochemical measures. As a result, clinical development plans and commercial strategies are reorienting toward integrated care models that bundle therapeutic benefits with adherence supports, diagnostic confirmation, and post-authorization evidence generation. Together, these shifts create new commercial archetypes and influence how stakeholders prioritize investment, access, and lifecycle planning.

A rigorous analysis of how tariff reforms in the United States in 2025 have influenced supply chain strategies, manufacturer decisions, and payer contracting dynamics in phenylketonuria care

Policy changes in trade and tariff regimes can have outsized implications for specialty therapies, manufacturing decisions, and supply chain resilience. The United States tariff adjustments introduced in 2025 have prompted stakeholders across the PKU value chain to reassess sourcing strategies, pricing models, and inventory planning. Manufacturers have responded by evaluating supplier diversification to mitigate cost exposure while maintaining stringent quality and regulatory compliance for biologics and complex small molecules.

Clinicians and health systems have observed that procurement cycles and reimbursement discussions are increasingly attentive to total cost of care and the potential for price leakage through import-dependent supply lines. In response, some developers have accelerated local manufacturing partnerships or adjusted logistics to prioritize continuity of supply for parenteral products and temperature-sensitive enzyme therapies. Concurrently, payers have signaled a greater focus on contracts that secure long-term affordability and predictable access, encouraging outcome-based agreements and risk-sharing arrangements. For patients and advocacy groups, the critical concern has been preserving uninterrupted access to essential therapies while ensuring affordability. Collectively, these dynamics are reshaping commercial negotiations, supplier strategies, and operational planning without altering clinical decision thresholds for individual patient care.

A comprehensive segmentation-driven synthesis that links therapeutic modality, administration route, patient age cohorts, and distribution channels to strategic development and access considerations

A nuanced segmentation approach reveals where clinical need, delivery modality, and channel dynamics intersect to influence care pathways and commercial opportunities. Based on Treatment Type, the landscape includes Gene Therapy & Enzyme Substitution Therapies, Nutritional Supplements, and Pharmacological Treatment, with the pharmacological category further delineated into Pegvaliase and Sapropterin Dihydrochloride, each with distinct clinical profiles, administration requirements, and adherence considerations. These therapeutic distinctions inform how clinicians select interventions across severity spectrums and how manufacturers position differentiated benefits such as onset of action, monitoring requirements, and long-term safety data.

Based on Route of Administration, the market is studied across Oral and Parenteral approaches, highlighting divergent patient experiences: oral regimens offer convenience and suitability for outpatient management, whereas parenteral modalities may deliver more potent biochemical control but require infrastructure for administration and monitoring. Based on Age Group, segmentation into Adults (18 years and above) and Pediatric (0-17 years) underscores the varying clinical objectives and support systems; pediatric care often centers on early developmental outcomes and family-centered adherence supports, while adult care emphasizes sustained neurocognitive functioning and comorbidity management. Based on Distribution Channel, the landscape includes Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Specialty Clinics & Treatment Centers, each channel presenting unique access considerations, payer interactions, and patient touchpoints for education, adherence reinforcement, and monitoring. Together, these segmentation dimensions create a matrix that companies and clinicians can use to align product attributes, service models, and go-to-market strategies with patient needs and healthcare system capabilities.

A strategic regional assessment showing how differing healthcare systems, screening programs, and manufacturing capabilities shape access to phenylketonuria therapies across global regions

Regional dynamics are central to understanding how clinical practice, regulatory pathways, and reimbursement systems influence the availability and adoption of PKU treatments. In the Americas, established newborn screening programs and concentrated centers of excellence support early diagnosis and longitudinal care, yet access challenges remain for patients outside metropolitan areas and for therapies that require specialized administration or monitoring. Policy dialogues in this region increasingly emphasize value-based contracting and expanded coverage for high-impact therapies, prompting manufacturers to design evidence-generation plans that resonate with payers as well as clinical stakeholders.

In Europe, Middle East & Africa, heterogeneity is pronounced: Western European markets typically exhibit mature reimbursement frameworks and organized patient registries that facilitate post-marketing evidence collection, while parts of the Middle East and Africa face infrastructure and access constraints that influence diagnostic reach and therapy adoption. Cross-border collaboration and capacity-building initiatives are emerging to address gaps in newborn screening and specialist care. In Asia-Pacific, rapid policy reform, investment in domestic biomanufacturing, and growing interest in rare disease policy are accelerating both clinical trial activity and localized supply chain strategies. Health systems in this region vary in their adoption of specialty therapies and in the development of reimbursement instruments tailored to rare disease treatments, which shapes manufacturer entry strategies and real-world evidence commitments.

An executive insight into how clinical data depth, manufacturing strategy, and integrated patient support offerings define competitive advantage among phenylketonuria therapy developers

Competitive dynamics in the phenylketonuria treatment landscape are shaped by product differentiation, clinical evidence depth, and ecosystem engagement strategies. Leading developers are investing in long-duration clinical studies and real-world evidence to demonstrate sustained biochemical control and functional outcomes, while also refining manufacturing processes to optimize scalability and cost-efficiency. Strategic partnerships with specialty clinics, patient advocacy organizations, and diagnostic laboratories are enhancing patient identification, enrollment in registries, and adherence support programs that complement therapeutic benefits.

Innovation in service delivery-such as integrated care pathways that link therapy initiation with nutritionists, digital monitoring tools, and telehealth follow-up-has become a competitive lever. Payers and provider networks are gravitating toward manufacturers who can offer comprehensive support bundles that reduce total cost of care and improve measurable patient outcomes. Additionally, companies pursuing advanced modalities are prioritizing regulatory engagement to clarify post-approval evidence requirements and to secure labeling that reflects long-term safety and functional benefits. Collectively, these approaches indicate that successful players will be those that pair robust clinical programs with pragmatic commercialization models and sustained stakeholder engagement.

A set of pragmatic, actionable recommendations that align clinical trial design, patient support services, supply resilience, and payer engagement to accelerate adoption and access

Industry leaders must align scientific ambition with pragmatic commercial and access strategies to ensure that therapeutic advances translate into measurable patient benefit. First, developers should prioritize study designs that include meaningful functional endpoints, patient-reported outcomes, and age-stratified analyses to satisfy both clinical and payer decision criteria. Second, integrating adherence-support services-digital monitoring, nutrition counseling, and telemedicine follow-up-can materially improve real-world outcomes and strengthen payer negotiations. Third, supply chain resilience should be built through supplier diversification, regional manufacturing partnerships, and contingency planning for temperature-sensitive and parenteral therapies.

Fourth, commercial teams should pursue outcome-based contracting pilots where feasible, coupling reimbursement to predefined clinical milestones that reflect patient-centered benefits. Fifth, collaboration with advocacy groups and specialist centers will accelerate patient identification and registries while enhancing post-approval surveillance. Finally, cross-functional alignment between regulatory, medical affairs, and market access teams will be critical to navigate evolving evidence expectations and to construct dossiers that balance long-term safety with real-world effectiveness. These combined actions will enhance adoption, preserve continuity of supply, and demonstrate value to payers and providers.

A transparent, multi-method research approach combining expert interviews, regulatory review, and literature synthesis to generate credible, actionable insights while acknowledging data limitations

This research synthesizes multiple evidence streams to produce balanced, reproducible insights. Primary research included structured interviews with clinical experts, specialty pharmacists, and patient advocacy leaders to capture frontline experiences of diagnosis, treatment initiation, and long-term management. Secondary research encompassed peer-reviewed literature, regulatory guidance documents, clinical trial registries, and health policy analyses to triangulate clinical efficacy, safety profiles, and evolving regulatory expectations. Data integrity was reinforced through cross-validation across sources, and methodological transparency was maintained by documenting interview protocols, inclusion criteria, and analytic frameworks.

Quantitative inputs were analyzed alongside qualitative insights to surface themes related to adherence, monitoring burdens, and payer considerations without projecting numerical estimates. Attention was given to temporal relevance by prioritizing sources and expert feedback from the most recent two-year horizon, ensuring that findings reflect current practice and policy shifts. Limitations were acknowledged; for example, regional heterogeneity in data availability and the inherent uncertainty around long-term outcomes for novel therapies were addressed by emphasizing robust evidence development pathways and adaptive post-authorization study designs. Overall, the methodology balances depth and credibility to inform strategic decisions across clinical, commercial, and policy domains.

A concise synthesis highlighting the interplay between clinical innovation, operational resilience, and stakeholder collaboration as the path to sustained patient benefit in phenylketonuria care

In conclusion, the phenylketonuria treatment landscape is at an inflection point where scientific progress intersects with practical imperatives for access and sustainability. Advances in gene therapy, enzyme substitution, and pharmacological options are expanding the therapeutic toolkit, but their full potential will be realized only through integrated strategies that address adherence, monitoring, and payer evidence needs. Supply chain and policy shifts, including tariff-related changes and regional manufacturing initiatives, underscore the importance of operational resilience alongside clinical innovation.

Going forward, successful stakeholders will be those who can translate clinical differentiation into durable real-world benefit through targeted evidence generation, robust patient support programs, and collaborative value propositions with payers and providers. Strengthening newborn screening, enhancing registries, and fostering multinational data-sharing will also be essential to characterize long-term outcomes and optimize care pathways. This conclusion synthesizes the report's core insights and points to concrete domains-clinical trial design, distribution strategies, and stakeholder engagement-where focused action can accelerate patient access and improve lifelong outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Phenylketonuria Treatment Market, by Treatment Type

  • 8.1. Gene Therapy & Enzyme Substitution Therapies
  • 8.2. Nutritional Supplements
  • 8.3. Pharmacological Treatment
    • 8.3.1. Pegvaliase
    • 8.3.2. Sapropterin Dihydrochloride

9. Phenylketonuria Treatment Market, by Route of Administration

  • 9.1. Oral
  • 9.2. Parenteral

10. Phenylketonuria Treatment Market, by Distribution Channel

  • 10.1. Offline
  • 10.2. Online

11. Phenylketonuria Treatment Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Phenylketonuria Treatment Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Phenylketonuria Treatment Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Phenylketonuria Treatment Market

15. China Phenylketonuria Treatment Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. American Gene Technologies
  • 16.7. APR Applied Pharma Research s.a.
  • 16.8. BioMarin Pharmaceuticals Inc
  • 16.9. Codexis, Inc.
  • 16.10. Daiichi Sankyo Co. Ltd.
  • 16.11. Galen Limited
  • 16.12. Homology Medicines, Inc.
  • 16.13. Nestle S.A.
  • 16.14. PIAM Farmaceutici S.P.A.
  • 16.15. Pluvia AS
  • 16.16. PTC Therapeutics, Inc.
  • 16.17. Relief Therapeutics Holding SA
  • 16.18. Sanofi group
  • 16.19. Synlogic
  • 16.20. Travere Therapeutics, Inc.
  • 16.21. Ultragenyx Pharmaceutical Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PHENYLKETONURIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PHENYLKETONURIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES PHENYLKETONURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA PHENYLKETONURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY GENE THERAPY & ENZYME SUBSTITUTION THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY GENE THERAPY & ENZYME SUBSTITUTION THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY GENE THERAPY & ENZYME SUBSTITUTION THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PEGVALIASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PEGVALIASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PEGVALIASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY SAPROPTERIN DIHYDROCHLORIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY SAPROPTERIN DIHYDROCHLORIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY SAPROPTERIN DIHYDROCHLORIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. AMERICAS PHENYLKETONURIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 35. AMERICAS PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. AMERICAS PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 39. NORTH AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. NORTH AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. NORTH AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 44. LATIN AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. LATIN AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. LATIN AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. EUROPE, MIDDLE EAST & AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 50. EUROPE, MIDDLE EAST & AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 51. EUROPE, MIDDLE EAST & AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. MIDDLE EAST PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. MIDDLE EAST PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. MIDDLE EAST PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 63. MIDDLE EAST PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 67. AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 68. AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. ASEAN PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. ASEAN PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. ASEAN PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 78. ASEAN PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. ASEAN PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. GCC PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GCC PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. GCC PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 83. GCC PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. GCC PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPEAN UNION PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPEAN UNION PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPEAN UNION PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPEAN UNION PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPEAN UNION PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. BRICS PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. BRICS PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. BRICS PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 93. BRICS PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. BRICS PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. G7 PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. G7 PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. G7 PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 98. G7 PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. G7 PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NATO PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. NATO PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NATO PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 103. NATO PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. NATO PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. UNITED STATES PHENYLKETONURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. UNITED STATES PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. UNITED STATES PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 109. UNITED STATES PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. UNITED STATES PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. CHINA PHENYLKETONURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. CHINA PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. CHINA PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 114. CHINA PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. CHINA PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)